BSG

Across TCGA pan-cancer cohorts, BSG mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated BSG data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher BSG mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated BSG expression acts as an unfavorable survival marker, although some lineages such as COAD and LSCC show a favorable association.

CCRCC, PDAC, and COAD are the cancer types where BSG mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.605	0.854	<.001	59	view →
PDAC	DFS	Quartile	III,IV	0.319	1.000	.002	32	view →
COAD	DFS	Median	III,IV	1.000	0.846	.049	6	view →
LSCC	OS	Median	II,III,IV	0.866	0.675	.018	5	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

BSG–CCRCC (DFS)

Open the CCRCC breakdown →